OSIR News Alert Osiris Therapeutics (OSIR) 14.87 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Osiris Therapeutics (OSIR) 14.87 $OSIR

Osiris inks deal with Stryker to commercialize bone matrix
Seeking Alpha - at Seeking Alpha - Wed Dec 24, 12:19PM CST

OSIR: 14.87 (+0.13), SYK: 96.00 (-0.61)

Cell Therapy 2015: With Maturity Comes Promise
Life Sciences Report - Seeking Alpha - Wed Dec 24, 6:41AM CST
A number of new and innovative medical paradigms are being explored by companies in the life sciences sector, with one of the front-runners being cell therapy - a disruptive technology that has, in the past few years, progressed out of preclinical...
KOOL: 1.13 (+0.04), AGEN: 3.85 (unch), INO: 9.11 (-0.09), NBS: 3.27 (+0.02), OSIR: 14.87 (+0.13), TEVA: 57.09 (+0.33), ATHX: 1.30 (-0.03)

Stryker & Osiris Team Up to Market Viable Bone Matrix - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 2:50PM CST
Under the partnership, Stryker Corporation (SYK) will attain exclusive, worldwide rights to Osiris' viable bone matrix under the name BIO4.
ANIP: 55.24 (+1.79), OSIR: 14.87 (+0.13), AFFX: 9.80 (+0.05), SYK: 96.00 (-0.61)

Osiris Announces a Strategic Partnership with Stryker for Marketing Osiris' Viable Bone Matrix
Business Wire - Mon Dec 22, 3:30PM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that it has entered into an exclusive, worldwide partnership with Stryker Corporation (NYSE:SYK) for the commercialization and development of Osiris' viable bone matrix tissue form. Stryker is a global leader in medical technology whose products and services are available in over 100 countries around the world. This partnership strategically aligns one of Osiris' leading regenerative medicine technologies with Stryker's innovative medical device portfolio; the resulting synergies will maximize the market potential.
OSIR: 14.87 (+0.13), SYK: 96.00 (-0.61)

Global Regenerative Medicine Market: 20.16% CAGR to 2019 Forecasts a New Research Report at ReportsnReports.com
PRWeb - Wed Dec 17, 10:30PM CST
The rise in prevalence of degenerative diseases is one of the main factors which is driving the growth of the global regenerative medicine market. Regenerative medicine is involved in the process of replacing or regenerating human tissues, cells and/or organs for normal functioning of the body. Small molecules and biologics, gene therapy, and cell therapy are the three main technologies which are used in regenerative medicine. The global market is expected to grow at a compound annual growth rate of 20.16% during the period from 2014 to 2019. Increase in demand for regenerative products and an increase in research and development are also fueling the growth in the global regenerative medicine market.
RTIX: 5.20 (unch), MDT: 74.08 (+0.31), PSTI: 2.46 (unch), OSIR: 14.87 (+0.13), OPXA: 0.80 (+0.01), FCSC: 2.38 (+0.04), BAX: 74.45 (-0.04), CYTX: 0.48 (-0.01)

Commit To Buy Osiris Therapeutics At $11, Earn 9.9% Annualized Using Options
at The Street - Mon Dec 15, 11:18AM CST
Investors considering a purchase of Osiris Therapeutics Inc shares, but cautious about paying the going market price of $12.83/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
OSIR: 14.87 (+0.13)

Is Osiris Therapeutics (OSIR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:34AM CST
Osiris Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OSIR: 14.87 (+0.13)

New medical chief at Osiris
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:13AM CST

OSIR: 14.87 (+0.13)

Osiris Therapeutics Announces Expansion of the Leadership Team
Business Wire - Wed Dec 03, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce the expansion of the management team with the appointment of Adrian Mollo as General Counsel and Dr. Jon Hopper as Chief Medical Officer, both reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. Gregory Law also recently joined the Osiris management team as Vice President of Finance and Principal Accounting Officer, reporting to Philip Jacoby, Chief Financial Officer.
OSIR: 14.87 (+0.13)

Osiris Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Dec 01, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. ET in New York City.
OSIR: 14.87 (+0.13)

Osiris Therapeutics Earnings Hindsight: Down 2.8% in Last 17 Days (OSIR)
Comtex SmarTrend(R) - Mon Nov 24, 9:24AM CST
Two weeks ago on November 7th, 2014 Osiris Therapeutics (NASDAQ:OSIR) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Since the company's report, shares of Osiris Therapeutics have fallen from $13.50 to $13.12, representing a loss of 2.8% in the past 17 days.
OSIR: 14.87 (+0.13)

Earnings Look Back: Osiris Therapeutics Is Down 3.3% Since Reporting Quarterly Results 1 Week Ago (OSIR)
Comtex SmarTrend(R) - Mon Nov 17, 3:25PM CST
When Osiris Therapeutics (NASDAQ:OSIR) reported earnings a week ago on November 7th, 2014, analysts, on average, expected the company to report a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Shares of Osiris Therapeutics have slipped from $13.50 to $13.05, representing a loss of 3.3%, since the company reported earnings 10 days ago.
OSIR: 14.87 (+0.13)

Osiris Therapeutics to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
Business Wire - Mon Nov 17, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 20, 2014 at 9:00 a.m. ET in New York City.
OSIR: 14.87 (+0.13)

Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 5.87 (+0.35), BIIB: 340.89 (+5.13), OSIR: 14.87 (+0.13), AMAG: 43.02 (+0.90)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST

AGTC: 20.96 (+0.22), BXE: 3.52 (-0.06), ROKA: 4.60 (-0.09), ALNY: 93.52 (+0.97), NCT: 4.68 (-0.02), SSRI: 4.66 (+0.26), ABCB: 25.94 (+0.23), OSIR: 14.87 (+0.13), XCO: 2.38 (-0.03), JDST: 19.26 (-2.21)

Osiris Therapeutics' (OSIR) CEO Lode Debrabandere on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 11:00AM CST

OSIR: 14.87 (+0.13)

Osiris ups revenues 149% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:19AM CST

OSIR: 14.87 (+0.13)

Osiris Therapeutics (OSIR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Nov 07, 7:55AM CST

OSIR: 14.87 (+0.13)

Osiris Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:10AM CST

OSIR: 14.87 (+0.13)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 65

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Tigerlily Brings HIV Information to Women’s Health

Updated Category News Views 99

A stubborn information gap is exactly where Tigerlily Foundation is planting its flag. The nonprofit’s new national HIV education and awareness campaign, THE POWER OF U, expands work that began in breast cancer advocacy into another area where women need clear facts, trusted voices, and room to speak without being shamed for needing answers. This is not a story that...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 10

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 115

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 122

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Classic Chevrolet Gives $1.145M to 13 Local Groups

Updated Category News Views 104

A Thanksgiving Check With Some Real Weight More than a million dollars changing hands before lunch is not the usual holiday fluff, and Classic Chevrolet's planned $1,145,040 donation deserves more than a quick nod. On Tuesday, November 24, at 11 a.m. CST, the Grapevine dealership says it will distribute that sum among 13 nonprofit organizations and charitable programs...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 52

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 96

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading

Top 5 Most Recently Viewed Articles

Antonio Filosa Takes the Helm as CEO of Stellantis N.V.

Updated Category News Views 335

Antonio Filosa Appointed as Stellantis N.V. Chief Executive Officer Stellantis N.V., a prominent player in the global automotive arena, has officially announced the appointment of Antonio Filosa as its new Chief Executive Officer. Filosa, who has amassed over 25 years of experience within the automotive sector, currently holds the position of Chief Operating Officer for...

Continue Reading
Understanding the Edwards Lifesciences Legal Landscape

Updated Category News Views 278

Understanding Recent Legal Issues for Investors In the world of investment, understanding legal implications can often feel overwhelming, especially when a company faces a class action lawsuit. Edwards Lifesciences Corporation, a name recognized for its innovative heart valve technologies, currently finds itself embroiled in legal battles that could shape its future and...

Continue Reading
Arrive Home and FormFree Join Forces to Enhance Homeownership Access

Updated Category News Views 155

Arrive Home Partners with FormFree for Innovative Solutions The innovative collaboration between Arrive Home and FormFree aims to transform the landscape of homeownership for many borrowers facing challenges due to limited credit histories. This partnership is particularly significant as it opens doors for those who have previously been overlooked by traditional credit...

Continue Reading
Verizon's $20 Billion Acquisition: A Strategic Expansion Ahead

Updated Category News Views 76

Verizon Announces Major Acquisition of Frontier Communications Verizon has recently made headlines by announcing a significant acquisition deal with Frontier Communications. This all-cash transaction, valued at $20 billion, underscores Verizon's dedication to substantially expanding its fiber network. Details of the Acquisition According to the proposed terms, Verizon...

Continue Reading
MoxiWorks Enhances Innovation Timeline with New Leadership and Funding

Updated Category News Views 174

MoxiWorks Enhances Innovation Timeline with New Leadership and Funding Funding from private equity and brokerage partners, along with new leadership, is set to transform MoxiWorks, a leading provider of sales and marketing software in the real estate sector. With substantial capital secured from its ownership group, which includes Vector Capital, Howard Hanna Real Estate...

Continue Reading